Contact Us
Drug Search Results
More Filters [+]

NM-003

Alternative Names: nm-003, nm 003, nm003
Latest Update: 2020-12-09
Latest Update Note: News Article

Product Description

Mechanisms of Action: GLP-2 Agonist

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: Orphan Drug - Graft vs Host Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 9 Meters Biopharma
Company Location: RALEIGH NC 27615
Company CEO: John Temperato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NM-003

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Graft vs Host Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

12/09/2020

News Article

 9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions